ClinicalTrials.gg
CompletedNCT00708422Updated Apr 23, 2012Results posted

Effects of Travatan Z and Xalatan on Ocular Surface Health

A Phase 4 interventional study of Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) and Latanoprost ophthalmic solution 0.005% (XALATAN®) in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-23.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.

Enrollment
9th of 39
231 · median 89
Started
2008
with 6 others
Phase 4
25 of 42
none open now
Registered
17th of 42
by date
Lead sponsor
27 of 42
Alcon Research

Among the 42 studies testing travoprost in Glaucoma, this one is the 9th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2008, is one of 25 in phase 4, and was the 17th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing travoprost in Glaucoma as a file.
02

Study summary

The purpose of this randomized, double-masked, parallel-group, multicenter study is to evaluate ocular surface effects after the administration of travoprost with SofZia® preservative system or Xalatan once daily for 12 weeks.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension

Keywords

  • Ocular surface health
  • OSDI
  • TFBUT
  • Glaucoma
  • Ocular hypertension
  • Corneal staining
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older.
  • Diagnosis of primary open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion) or ocular hypertension in at least one eye (study eye).
  • Use of BAK (benzalkonium chloride) containing intraocular pressure (IOP) lowering medication for a minimum of one year, including latanoprost (Xalatan®) monotherapy for at least 6 months prior to Visit 1.
  • IOP controllable and stable on the study medication alone (both eyes).
  • Believed to have ocular surface disease (OSD).
  • Tear Break-up Time (TBUT) of ≤ 6 seconds in the study eye.
  • Willing and able to discontinue the use of any topical ocular medication other than the study medication or BAK free artificial tears for the duration of the study.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Current use or use within the last 3 months of cyclosporine ophthalmic emulsion 0.05% (Restasis®), topical ocular , or topical ocular non-steroidal anti-inflammatory drugs.
  • Current use of punctual plugs.
  • Women of not using reliable means of .
  • Women who are pregnant or lactating.
  • Suspected or diagnosed with Sjogrens's syndrome.
  • Current use of any brand of artificial tears containing BAK.
  • Use of any systemic medications on a chronic basis not on a stable dosing regimen for at least 30 days prior to Visit 1, or an anticipated change in dosing regimen of medications during the course of the study.
  • Intraocular conventional surgery or laser surgery in study eyes less than six months prior to Visit 1.
  • Current use of contact lenses within 30 days of Visit 1.
  • Participation in any other study within 30 days prior to Visit 1.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    Travoprost

    One drop self-administered in the study eye(s) once daily at night for 12 weeks

    Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

  • Active comparator
    Latanoprost

    One drop self-administered in the study eye(s) once daily at night for 12 weeks

    Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)

Interventions

  • DrugTravoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

    Drug page: Travoprost

    Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.

    Also known as: TRAVATAN Z®, travoprost

  • Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.

    Also known as: XALATAN®, latanoprost

06

What researchers measure

Primary outcomes

  1. Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT)

    Tear film break-up time was assessed by the same examiner both visits using the same slitlamp/settings. Examiner instilled fluorescein onto the patient's eye, after which the patient blinked several times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to time the occurrence of the first break in the fluorescein film. Three consecutive measurements were taken and averaged for actual TBUT. TBUT at Baseline (Day 0) was subtracted from TBUT at 12 weeks (Day 84) and reported as change. A higher number represents a lengthening in the tear film break up time.

    Time frame: 12 weeks (Day 84)

Secondary outcomes

  1. Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

    The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 12-week OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.

    Time frame: 12 weeks (Day 84)

07

Results

Posted Apr 23, 2012
Limitations and caveats
The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge (Pflugfelder and Baudoin, 2011).

Participant flow

Patients were recruited from 21 US study centers. Eligible patients having a diagnosis of open-angle glaucoma or ocular hypertension and abnormal TBUT were enrolled.

Participant flow — Overall Study
MilestoneTravoprostLatanoprost
Started116115
Completed112114
Not completed41
Withdrew: Adverse event31
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryMean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT)

Tear film break-up time was assessed by the same examiner both visits using the same slitlamp/settings. Examiner instilled fluorescein onto the patient's eye, after which the patient blinked several times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to time the occurrence of the first break in the fluorescein film. Three consecutive measurements were taken and averaged for actual TBUT. TBUT at Baseline (Day 0) was subtracted from TBUT at 12 weeks (Day 84) and reported as change. A higher number represents a lengthening in the tear film break up time.

Time frame:
12 weeks (Day 84)
Reported as:
Mean · seconds
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT)
secondsTravoprostLatanoprost
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT)0.8 ± 1.51.1 ± 2.7
SecondaryMean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 12-week OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.

Time frame:
12 weeks (Day 84)
Reported as:
Mean · Units on a scale
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
Units on a scaleTravoprostLatanoprost
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score-0.0 ± 11.4-1.3 ± 16.7

Adverse events

Collected over Adverse events were collected for the duration of the study: 11 July 2008 through 03 August 2009.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travoprost—1/116 (0.9%)0/116 (0%)
Latanoprost—1/115 (0.9%)0/115 (0%)
Most frequent serious events
Most frequent serious events
EventTravoprostLatanoprost
Gastrointestinal DisorderGastrointestinal disorders0/1161/115
CellulitisInfections and infestations1/1160/115

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TravoprostLatanoprostTotal
<=18 years000
Between 18 and 65 years344478
>=65 years7870148
Sex: Female, Male
Sex: Female, Male(Participants)TravoprostLatanoprostTotal
Female7466140
Male384886
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2008
First posted
Jul 2, 2008
Start
Jul 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Apr 23, 2012
Last update
Apr 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00708422
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jul 2, 2008
Start date
Jul 2008
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Apr 23, 2012
Last update
Apr 23, 2012

Study contacts

Judy Vittitoe, RN, MPH
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion